Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
39
Lung Cancer:<br />What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting
-
Upload
belinda-knight -
Category
Documents
-
view
214 -
download
1
Transcript of Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
Lung Cancer:<br />What’s New and What’s Old?
Presented By Leora Horn at 2014 ASCO Annual Meeting
Outline Slide
Presented By Leora Horn at 2014 ASCO Annual Meeting
Slide 3
Presented By Leora Horn at 2014 ASCO Annual Meeting
LUX-Lung 3 and 6: design
Presented By Leora Horn at 2014 ASCO Annual Meeting
Combined OS analysis: common mutations (n=631)
Presented By Leora Horn at 2014 ASCO Annual Meeting
Combined OS analysis: mutation categories
Presented By Leora Horn at 2014 ASCO Annual Meeting
JO25567 Study Design
Presented By Leora Horn at 2014 ASCO Annual Meeting
Primary endpoint: PFS by independent review
Presented By Leora Horn at 2014 ASCO Annual Meeting
PFS by EGFR Mutation Type
Presented By Leora Horn at 2014 ASCO Annual Meeting
Acquired Resistance to EGFR TKIs
Presented By Leora Horn at 2014 ASCO Annual Meeting
Phase I Trials With Third Generation EGFR Inhibitors
Presented By Leora Horn at 2014 ASCO Annual Meeting
Phase I Trials
Presented By Leora Horn at 2014 ASCO Annual Meeting
AZD9291: Response rate* in T790M+ (central test)
Presented By Leora Horn at 2014 ASCO Annual Meeting
CO-1686: Best response in Phase 1 and early <br />Phase 2 expansion cohort patients
Presented By Leora Horn at 2014 ASCO Annual Meeting
HM61713: Response in T790M Cohort
Presented By Leora Horn at 2014 ASCO Annual Meeting
RADIANT Trial Design
Presented By Leora Horn at 2014 ASCO Annual Meeting
Disease-free Survival KM Plot – FAS
Presented By Leora Horn at 2014 ASCO Annual Meeting
Slide 18
Presented By Leora Horn at 2014 ASCO Annual Meeting
Slide 19
Presented By Leora Horn at 2014 ASCO Annual Meeting
Summary
Presented By Leora Horn at 2014 ASCO Annual Meeting
PROFILE 1014 Study Design
Presented By Leora Horn at 2014 ASCO Annual Meeting
Primary Endpoint Met: Crizotinib Superior to Pemetrexed-based Chemotherapy in Prolonging PFSa
Presented By Leora Horn at 2014 ASCO Annual Meeting
ASCEND-1 Study Design
Presented By Leora Horn at 2014 ASCO Annual Meeting
Progression-Free Survival in Patients with ALK+ NSCLC
Presented By Leora Horn at 2014 ASCO Annual Meeting
Summary
Presented By Leora Horn at 2014 ASCO Annual Meeting
REVEL: Study Design
Presented By Leora Horn at 2014 ASCO Annual Meeting
Overall Survival<br />ITT Population
Presented By Leora Horn at 2014 ASCO Annual Meeting
Study Design: Squire
Presented By Leora Horn at 2014 ASCO Annual Meeting
Slide 29
Presented By Leora Horn at 2014 ASCO Annual Meeting
Summary
Presented By Leora Horn at 2014 ASCO Annual Meeting
CREST Trial Design
Presented By Leora Horn at 2014 ASCO Annual Meeting
Overall survival
Presented By Leora Horn at 2014 ASCO Annual Meeting
PCI in SCLC: Trial Design
Presented By Leora Horn at 2014 ASCO Annual Meeting
Time to Brain Metastasis
Presented By Leora Horn at 2014 ASCO Annual Meeting
Overall Survival
Presented By Leora Horn at 2014 ASCO Annual Meeting
Summary
Presented By Leora Horn at 2014 ASCO Annual Meeting
KEYNOTE-001: First line therapy with MK3475 in patients with PD-L1 positive NSCLC
Presented By Leora Horn at 2014 ASCO Annual Meeting
Antitumor Activity by MK-3475 Dose
Presented By Leora Horn at 2014 ASCO Annual Meeting
Conclusions
Presented By Leora Horn at 2014 ASCO Annual Meeting
